Myanmar Regional Center of Excellence for Malaria Research

缅甸疟疾研究区域卓越中心

• 批准号: 9263316
• 负责人: Myaing Myaing Nyunt
• 金额: $ 139.6万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-04-12 至 2018-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9263316
• 关键词: Africa; Antigens; Area; Artemisinins; Asia; Bangladesh; Biological Assay; China; Clinical; Cohort Studies; Conflict (Psychology); Country; Culicidae; Data; Democracy; Disease; Drug resistance; Entomology; Epidemiology; Exposure to; Falciparum Malaria; Far East; Foundations; Genetic Variation; Goals; Grant; Health system; Human; Interdisciplinary Study; Knowledge; Lead; Legal patent; Malaria; Measures; Modeling; Molecular; Monitor; Myanmar; National Institute of Allergy and Infectious Disease; Parasites; Pattern; Peptides; Plasmodium falciparum; Plasmodium vivax; Population; Population Genetics; Prevention; Proteins; Recommendation; Research; Resistance; Resistance to infection; Risk; Sampling; Series; Serological; Side; Site; Source; Southeastern Asia; Structure; Testing; Time; Vivax Malaria; World Health; World Health Organization; base; clinical epidemiology; clinical risk; design; epidemiology study; evidence base; genetic approach; genomic epidemiology; in vivo; innovation; malaria infection; malaria transmission; migration; molecular marker; programs; prospective; southeast Asian; symposium; tool; transmission process; vector

OVERVIEW Myanmar Regional Center of Excellence for Malaria Research Shortly before NIAID announced the ICEMR program in 2009, artemisinin-resistant falciparum malaria appeared in Southeast Asia [1,2], posing a serious threat to global malaria control and elimination [3,4]. As a leading center for research on the emergence and spread of drug resistant malaria in Africa [5-9], our group was asked by the World Health Organization (WHO) and regional partners to help design and lead a series of clinical and genomic epidemiology studies to identify and validate molecular markers for artemisinin resistance in Asia [10-15]. Based in part on our findings about the patterns of emergence and spread of artemisinin resistance in the region [14], in 2015 the WHO abandoned its strategy of trying to contain artemisinin resistance, and the World Health Assembly approved a new WHO recommendation to launch a campaign to completely eliminate falciparum malaria in Southeast Asia [16]. Along with other countries at the 2015 East Asia Summit, Myanmar, the emerging democracy formerly known as Burma, and the Southeast Asian country with by far the greatest malaria burden [17], endorsed a plan for malaria elimination in the region by 2030. To achieve this daunting goal, innovative tools are needed for malaria surveillance, treatment and prevention. Because the heaviest concentrations of malaria in Myanmar and neighboring countries are found in border and conflict areas that are often out of reach of national health systems, malaria elimination—and malaria research in support of elimination—requires a multi-sectoral, cross-border approach. Building on the foundation of a successful malaria research program that we created in Myanmar in 2012 with NIAID grant support, and working closely with local and regional partners, we now propose to establish a new ICEMR centered in Myanmar, with sites in central Myanmar and on both sides of its borders with China and Bangladesh. Integrating findings from clinical and field research, including molecular surveillance, genomic epidemiology and geospatial mapping and modeling of malaria risk, we will conduct innovative multidisciplinary research that will provide essential knowledge, tools, and evidence-based strategies for national malaria control programs and their partners to control, treat and ultimately eliminate malaria in Southeast Asia.

缅甸地区疟疾研究英才中心概览 就在NIAID于2009年宣布ICEMR计划前不久，抗青蒿素恶性疟疾 出现在东南亚[1，2]，对全球疟疾控制和消除构成严重威胁[3，4]。作为一名 我们小组领导的非洲耐药疟疾出现和传播研究中心[5-9] 应世界卫生组织(WHO)和区域合作伙伴的要求，帮助设计和领导一系列 确定和验证青蒿素耐药性分子标记的临床和基因组流行病学研究 在亚洲[10-15]。部分基于我们对青蒿素出现和传播模式的发现 该地区的抗药性[14]，世卫组织在2015年放弃了试图控制青蒿素的战略 耐药性，世界卫生大会批准了世卫组织的一项新建议，即发起一项运动，以 在东南亚彻底消灭恶性疟疾[16]。与其他国家和地区一起参加2015年的东方 亚洲峰会，缅甸，前称缅甸的新兴民主国家，以及这个东南亚国家 到目前为止疟疾负担最重的国家[17]批准了一项到2030年在该地区消除疟疾的计划。 为了实现这一艰巨的目标，需要有监测、治疗和治疗疟疾的创新工具。 预防。因为缅甸和邻国的疟疾密度最高的是#年。 边界和冲突地区，国家卫生系统往往达不到，消除疟疾--以及 支持消除疟疾的研究--需要采取多部门、跨国界的方法。建立在 成立了一个成功的疟疾研究项目，我们于2012年在缅甸用NIAID的赠款创建了该项目 支持并与当地和区域伙伴密切合作，我们现在提议建立一个新的国际经济、社会和文化权利国际中心 以缅甸为中心，在缅甸中部以及与中国和 孟加拉。整合临床和现场研究的结果，包括分子监测、基因组学 在流行病学和地理空间制图以及疟疾风险建模方面，我们将进行创新的多学科 将为国家疟疾提供基本知识、工具和循证战略的研究 控制方案及其合作伙伴在东南亚控制、治疗并最终消灭疟疾。